3Brain AG Company Profile

Background

3Brain AG, established in 2011 and headquartered near Zürich, Switzerland, is a pioneering biotech firm specializing in microchip-based technologies for life science research. The company's mission is to revolutionize scientific research by integrating big data into life sciences, thereby enhancing the understanding of organs and related illnesses. With over two decades of scientific advancements, 3Brain has expanded its operations to include a branch in Genova, Italy, focusing on scientific validation activities, and a base in the United States to cater to a global clientele.

Key Strategic Focus

3Brain AG's strategic focus centers on developing microchip-based technologies that bridge the gap between biology and microelectronics. The company aims to provide researchers with tools that offer high-resolution, real-time data on cellular activities, thereby improving the efficiency and accuracy of preclinical studies. Their core objectives include:

Advancing Drug Discovery: By integrating microchips and artificial intelligence, 3Brain's technologies facilitate the collection and analysis of extensive cellular data, enhancing the selection process of drug candidates before clinical trials.

Enhancing Research in Neuroscience and Cardiology: The company's products are designed to study complex cellular networks, particularly in the brain and heart, enabling a deeper understanding of neurological and cardiac conditions.

Developing 3D Cell-Electronic Interfaces: With innovations like the Accura-3D microchip, 3Brain enables researchers to investigate three-dimensional cellular networks at unprecedented depths and resolutions.

Financials and Funding

As of 2025, 3Brain AG has an estimated annual revenue of $9.8 million, with a workforce of approximately 58 employees. The company has experienced a 62.5% growth in employee count over the past year. Specific details regarding total funding and valuation are not publicly disclosed.

Technological Platform and Innovation

3Brain AG distinguishes itself through several proprietary technologies and innovative methodologies:

CorePlate™ Technology: This platform integrates microchips into multiwell plates, transforming them into intelligent devices capable of collecting and processing extensive cellular data. The technology leverages artificial intelligence to simplify data interpretation, thereby enhancing the drug discovery process.

Accura-3D Microchip: Developed in collaboration with CSEM, this first-in-class 3D CMOS microchip features sensory gold-electrodes mounted on biopolymer-covered microneedles. It allows for the investigation of three-dimensional cellular networks, providing researchers with unprecedented access to complex biological systems.

High-Density Microelectrode Arrays (HD-MEAs): These platforms, such as BioCAM DupleX and BioCAM X, offer high-resolution, real-time recording and analysis of neuronal network activity, facilitating advanced research in neuroscience.

Leadership Team

3Brain AG's leadership comprises experienced professionals dedicated to advancing the company's mission:

Mauro Gandolfo: Co-founder and Chief Executive Officer, overseeing strategic direction and operations.

Alessandro Maccione: Co-founder and Chief Scientific Officer, leading scientific research and development initiatives.

Kilian Imfeld: Co-founder and Chief Technology Officer, responsible for technological innovation and product development.

In June 2021, Dr. Andrew Thomas joined the board of directors as Chairman, bringing additional expertise to the company's governance.

Competitor Profile

Market Insights and Dynamics

The biotech industry, particularly in the realm of microchip-based life science research tools, is experiencing significant growth. The demand for advanced technologies that enhance drug discovery and preclinical research is driving innovation and competition in this sector.

Competitor Analysis

Key competitors in the market include:

Axion BioSystems: Specializes in microelectrode array (MEA) systems for in vitro electrophysiology, focusing on neural and cardiac applications.

Multi Channel Systems (MCS): Offers a range of electrophysiological recording systems, including MEAs, for neuroscience research.

MaxWell Biosystems: Provides high-resolution electrophysiology platforms for drug discovery and basic research, emphasizing high-content screening capabilities.

These companies, like 3Brain AG, are dedicated to advancing research tools that facilitate a deeper understanding of complex biological systems.

Strategic Collaborations and Partnerships

3Brain AG has engaged in significant collaborations to enhance its technological capabilities:

CSEM Partnership: Collaborated with the Swiss applied research institute CSEM to develop the Accura-3D microchip, combining expertise in precision manufacturing and microelectronics.

SuSoS AG Agreement: Entered a commercialization agreement with SuSoS AG to ensure the adoption of 3Brain's high-resolution microelectrode arrays and CorePlate™ technologies, leveraging SuSoS' surface functionalization expertise.

Operational Insights

3Brain AG's strategic positioning is bolstered by its commitment to innovation and quality. The company's integration of microelectronics and biology has resulted in significant enhancements in statistical significance and success rates, optimizing kinetic assays and screening experiments. Designed in Switzerland, 3Brain's products adhere to the highest standards, providing researchers with reliable and precise tools for their studies.

Strategic Opportunities and Future Directions

Looking ahead, 3Brain AG aims to:

Expand Product Offerings: Develop additional formats of CorePlate™ devices, including 24-well and 96-well versions, to cater to a broader range of research needs.

Enhance AI Integration: Further integrate artificial intelligence into their platforms to streamline data analysis and interpretation, thereby accelerating the drug discovery process.

Strengthen Global Presence: Continue expanding their global footprint, particularly in the United States, to better serve the diverse needs of researchers worldwide.